BIOSECURE Act: A Challenge for China, An Opportunity for Taiwan Biotech

On September 9, 2024, the House of Representatives passed HR 8333,1 commonly known as the BIOSECURE Act.2 The bill passed 306-81, far exceeding the two thirds vote required to pass.

 
As we know the impact to China Pharmaceutical company is huge in near future. However, is it beneficial to other country ? like Taiwan?

 
According to press, The named China company could be - BGI Group, MGI, Complete Genomics, WuXi AppTec, WuXi Biologics, and which include gene therapy , small and biological company. The market of Small molecule drug is crowded and competition. Thus, biologic drug market will be a chance for Taiwan CDMO and API pharmaceutical company. As for gene therapy, we cannot ignore China presence , the development is beyond our understanding due to regulation is still not clear in China.

 
we can keep optimistic for Taiwan biotech company to expand business in USA in the near future if we can find right strategy, recruit talent and keep global market insight. On the other hand, how to leverage international partners is also crucial for global competition.

Let's work together!